Candesartan Cilexetil；坎地沙坦酯
货号：
IC3400
品牌：
Jinpan
暂无详情
暂无详情
产品简介
| MDL | MFCD00871371 |
| EC | EINECS 627-030-2 |
| InChIKey | GHOSNRCGJFBJIB-UHFFFAOYSA-N |
| InChI | InChI=1S/C33H34N6O6/c1-3-42-32-34-28-15-9-14-27(31(40)43-21(2)44-33(41)45-24-10-5-4-6-11-24)29(28)39(32)20-22-16-18-23(19-17-22)25-12-7-8-13-26(25)30-35-37-38-36-30/h7-9,12-19,21,24H,3-6,10-11,20H2,1-2H3,(H,35,36,37,38) |
| PubChem CID | 2540 |
| 别名 | 坎地沙坦西来替昔酯; TCV-116 |
| CAS | 145040-37-5 |
| 分子式 | C33H34N6O6 |
| 分子量 | 610.66 |
| 储存条件 | -20℃ |
| 纯度 | ≥98% |
| 单位 | 瓶 |
| 生物活性 | Candesartan Cilexetil (TCV-116) is an angiotensin II receptor antagonist used mainly for the treatment of hypertension[1]. |
| In Vivo | In rats, TCV-116 inhibited the pressor responses to Ang I, Ang II, and Ang III without an effect on the bradykinin (BK)-induced depressor response. In SHR, the antihypertensive effect of TCV-116 (10 mg/kg) was larger than the maximum antihypertensive effect of enalapril and was not intensified by combination with enalapril. TCV-116 is more effective than enalapril in reducing blood pressure in SHR and 1K, 1C-HR, and that the BK- and/or prostaglandin-potentiating effect of enalapril contributes little to its antihypertensive mechanism in SHR [2]. |
| SMILES | O=C(C1=C2C(N=C(OCC)N2CC3=CC=C(C4=CC=CC=C4C5=NNN=N5)C=C3)=CC=C1)OC(OC(OC6CCCCC6)=O)C |
| 靶点 | Angiotensin Receptor |
| 数据来源文献 | [1]. Pfeffer, M.A., et al., Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet, 2003. 362(9386): p. 759-66. [2]. Wada, T., et al., Comparison of the antihypertensive effects of the new angiotensin II (AT1) receptor antagonist candesartan cilexetil (TCV-116) and the angiotensin converting enzyme inhibitor enalapril in rats. Hypertens Res, 1996. 19(2): p. 75-81. |
| 规格 | 500mg 1g |
一种特异性的，非肽类血管生成素II受体（ATR）拮抗剂。